Although it was initially thought that this was not possible, in recent years, specific inhibitors that bind directly to these proteins have been beginning to emerge, most of them targeting KRAS, since it is one of the most frequently mutant protein in human neoplasia. The gene discussed is KRAS; the disease is neoplasm.